Linezolid

Please note: This is for information only.

Refer to local guidelines for treatment recommendations.


  • A new oxazolidinone antibiotic
  • Excellent bioavailability when given orally.
  • Usual adult dose: 600mg twelve hourly – oral or IV
  • Usual duration 10-14 days not advised for treatment of longer that 28 days.
  • No dosage reduction necessary if renal impairment
  • A reversible, non-selective inhibitor of monoamine oxidase. Has no antidepressive activity at antibacterial doses.

 

Precautions (for complete list see manufacturer's datasheet.)

  • Patients should be advised to avoid ingesting excessive amounts of food and drinks with a high tyramine content (e.g. mature cheese, yeast extracts, undistilled alcoholic beverages and fermented soya bean products such as soy sauce).
  • Close monitoring of blood pressure required if taking MAOIs, SSRIs, TCAs, dopaminergics, pethidine, or if patient has uncontrolled hypertension, thyrotoxicosis, bipolar depressive disorder or schizophrenia.
  • Check full blood count weekly for all patients during therapy – myelosuppression possible.
  • Patients should be advised to report any visual impairment such as changes in acuity, colour vision or field defects. Patients who require >28 days therapy should have regular formal visual assessments. Treatment may only be continued beyond 28 days on the advice of a Consultant and the rationale for extended treatment should be clearly documented in the patient's medical record.
  • Patients should be advised to report any signs of neuropathy, anaemia, thrombocytopenia or lactic acidosis.

Main indications:

  • Microbiology advice only– restricted agent
  • Resistant enterococcal infections (VRE).
  • Resistant staphylococcal infections.

Active against most strains of:

  • Enterococcus
  • Staphylococcus aureus – including MRSA
  • Streptococcus
  • Anaerobes

Not active against most strains of:

  • Haemophilus influenzae
  • Moraxella
  • Neisseria spp
  • Pseudomonas
  • E coli
  • Klebsiella